111 related articles for article (PubMed ID: 8976015)
1. Catechol-O-methyltransferase inhibition increases the uptake of 11C-3-(3,4-dihydroxyphenyl)-L-alanine in the rat pancreas.
Bergström M; Lu L; Marquez M; Moulder R; Jacobsson G; Ogren M; Eriksson B; Watanabe Y; Långström B
Scand J Gastroenterol; 1996 Dec; 31(12):1216-22. PubMed ID: 8976015
[TBL] [Abstract][Full Text] [Related]
2. Modulation of organ uptake of 11C-labelled L-DOPA.
Bergström M; Lu L; Marquez M; Fasth KJ; Bjurling P; Watanabe Y; Eriksson B; Långström B
Nucl Med Biol; 1997 Jan; 24(1):15-9. PubMed ID: 9080470
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase inhibition protects against 3,4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity.
Blessing H; Bareiss M; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2003 Jan; 42(2):139-51. PubMed ID: 12421594
[TBL] [Abstract][Full Text] [Related]
4. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Männistö PT; Tuomainen P; Tuominen RK
Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
6. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
7. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
[TBL] [Abstract][Full Text] [Related]
8. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
Kaakkola S; Wurtman RJ
J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
[TBL] [Abstract][Full Text] [Related]
9. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Napolitano A; Zürcher G; Da Prada M
Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
[TBL] [Abstract][Full Text] [Related]
10. Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons.
Storch A; Blessing H; Bareiss M; Jankowski S; Ling ZD; Carvey P; Schwarz J
Mol Pharmacol; 2000 Mar; 57(3):589-94. PubMed ID: 10692500
[TBL] [Abstract][Full Text] [Related]
11. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.
Acquas E; Carboni E; de Ree RH; Da Prada M; Di Chiara G
J Neurochem; 1992 Jul; 59(1):326-30. PubMed ID: 1613509
[TBL] [Abstract][Full Text] [Related]
12. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
Waters C
J Am Geriatr Soc; 2000 Jun; 48(6):692-8. PubMed ID: 10855610
[TBL] [Abstract][Full Text] [Related]
13. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Brannan T; Martínez-Tica J; Yahr MD
Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
[TBL] [Abstract][Full Text] [Related]
14. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
15. Extending levodopa action: COMT inhibition.
Martínez-Martín P; O'Brien CF
Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.
Günther I; Psylla M; Reddy GN; Antonini A; Vontobel P; Reist HW; Zollinger A; Nickles RJ; Beer HF; Schubiger PA
Nucl Med Biol; 1995 Oct; 22(7):921-7. PubMed ID: 8547890
[TBL] [Abstract][Full Text] [Related]
17. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
Männistö PT; Tuomainen P
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):412-8. PubMed ID: 1766471
[TBL] [Abstract][Full Text] [Related]
18. Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats.
Qi Q; Cao L; Li F; Wang H; Liu H; Hao H; Hao K
Xenobiotica; 2015; 45(9):820-7. PubMed ID: 25869243
[TBL] [Abstract][Full Text] [Related]
19. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
20. Central action of benserazide after COMT inhibition demonstrated in vivo by PET.
Tedroff J; Hartvig P; Bjurling P; Andersson Y; Antoni G; Långström B
J Neural Transm Gen Sect; 1991; 85(1):11-7. PubMed ID: 1867835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
